Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
This marks Enhertu's sixth approved indication in the country, Daiichi noted. Back in 2020, the China Center for Drug Evaluation designated Enhertu a "breakthrough therapy" for the second-line gastric ...
Daiichi Sankyo has expanded its presence in Canada with the official opening of its permanent headquarters in Toronto, ...
T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...
DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...
AstraZeneca Pharma India Limited has received a final assessment order from the Assessment Unit of the Income Tax Department for the assessment year 2022-23, involving ...
AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory ...
EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
The EMA has started its review of Daiichi Sankyo and AstraZeneca's Enhertu as a first-line therapy for HER2-positive breast ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for Enhertu ...
(Alliance News) - Daiichi Sanyko Co Ltd on Monday said EU regulators had validated an application for its breast cancer treatment, Enhertu with pertuzumab, jointly developed with AstraZeneca PLC. This ...
ENHERTU Plus Pertuzumab Type II Variation Application Validated in EU as First-Line Treatment of Patients with HER2 Positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback